Menu

Biosimilars/News

Clinical Trials V13F14

Mylan starts phase III trials for biosimilar insulin glargine

Biosimilars/News | Posted 03/10/2014

Generics maker Mylan has started two US phase III clinical trials for a biosimilar version of French drugmaker Sanofi’s diabetes drug Lantus (insulin glargine).

picture16

Long-term safety study of biosimilar anti-TNF initiated

Biosimilars/News | Posted 18/04/2014

The Polish Society of Gastroenterology is starting an observational trial to study the long-term safety of anti-tumour necrosis factor (TNF) antibodies, including biosimilars, in the treatment of inflammatory bowel disease (IBD), according to ClinicalTrials.gov.

11 AA010165

Roche updates position on biosimilars

Biosimilars/News | Posted 26/09/2014

Originator pharma company Roche has updated its position statement on biosimilars, stating that ‘biosimilars are not quite the same’.

Approved V13G05

Pegteograstim biological approved in South Korea

Biosimilars/News | Posted 19/09/2014

South Korean biologicals company, Green Cross, announced on 18 August 2014 that it had received marketing authorization from South Korea’s Ministry of Food and Drug Safety (MFDS) for its pegteograstim biological Neurapeg.

Insulin 1 V13C03

European approval for biosimilar insulin

Biosimilars/News | Posted 12/09/2014

Partners Eli Lilly and Boehringer Ingelheim, announced on 10 September 2014 that they had received European Commission (EC) approval for its biosimilar insulin glargine product Abasria (LY2963016), a first for Europe.

Remsima V14A10

Infliximab biosimilar to be distributed by Mundipharma

Biosimilars/News | Posted 05/09/2014

Celltrion’s infliximab biosimilar Remsima will be distributed in Belgium, Germany, Italy, Luxembourg, The Netherlands and UK, exclusively by Mundipharma International and its independent associated companies. Remsima is a biosimilar of Johnson and Johnson (J&J) and Merck’s anti-inflammatory blockbuster Remicade (infliximab).

Checklist V14A17

FDA receives application for monoclonal antibody biosimilar

Biosimilars/News | Posted 29/08/2014

South Korean biotechnology company Celltrion announced on 11 August 2014 that the company had, on 8 August 2014, completed the filing procedure to obtain US Food and Drug Administration (FDA) approval for its infliximab biosimilar.

24 AA011041

Merck KGaA to invest Euros 100 million in biosimilars

Biosimilars/News | Posted 23/05/2014

Germany’s Merck KGaA is looking for new sources of growth, one of which it sees as being biosimilars.

Insulin 1 V13C03

FDA grants tentative approval for insulin treatment

Biosimilars/News | Posted 22/08/2014

On 18 August 2014, the US Food and Drug Administration (FDA) granted tentative approval for a new insulin glargine product (LY2963016).

Teamwork original

More biosimilars collaborations on the cards

Biosimilars/News | Posted 22/08/2014

Collaborations for biosimilars are still in vogue, with the latest companies making deals being PlantForm Corporation (PlantForm) with PharmaPraxis and Oncobiologics and Laboratorios Liomont.